Drugs / VV119
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07240636 | Nov 2025 → Oct 2026 expected | — | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT06504290 | Jul 2024 → Jul 2026 overdue | schizophrenia | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT06105151 | Oct 2023 → Dec 2025 overdue | schizophrenia | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07703956 | Jul 2026 → Oct 2027 expected | schizophrenia | Vigonvita Life Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504290 ↗ |
| Route | Oral | “Subjects will receive VV119 orally for single dose.” NCT06105151 ↗ |